Granted Patent
B2
US 12,503,501 · App. 18/507,265 · Granted Dec 23, 2025
Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
Inventors:
William H. Frey, II (White Bear Lake, MN); Leah Ranae Bresin Hanson (Vadnais Heights, MN); Sharon Pokropinski (Schaumburg, IL); Francisco M. Rausa, III (Vernon Hills, IL)
Assignee:
Takeda Pharmaceutical Company Limited
C07K16/18A61K9/0043A61K31/401A61K31/4172C07K16/06A61K9/08A61K31/198A61K2039/505A61K2039/543C07K2317/21C07K2317/55C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
Claims (13)
1 . A method for delivering full-length immunoglobulin G (IgG) to the brain of the subject, the method comprising intranasally administering a composition comprising full-length IgG to the subject, wherein at least 40% of the full-length IgG administered to the subject contacts the contacts the upper third of the nasal cavity of the subject.
2 . The method of claim 1 , wherein administering the composition comprises administration of a liquid drop of the composition directly onto the nasal epithelium of the subject.
3 . The method of claim 1 , wherein administering the composition comprises directed administration of an aerosol of the composition to the nasal epithelium of the subject.
4 . The method of claim 3 , wherein the aerosol of the composition is a liquid aerosol.
5 . The method of claim 3 , wherein the aerosol of the composition is a powder aerosol.
6 . The method of claim 1 , wherein the composition does not contain a permeability enhancer.
7 . The method of claim 1 , wherein the composition consists essentially of pooled human IgG and an amino acid selected from the group consisting of glycine, histidine, and proline.
8 . The method of claim 1 , wherein at least 50% of the full-length IgG administered to the subject contacts the upper third of the nasal cavity of the subject.
9 . The method of claim 1 , wherein at least 60% of the full-length IgG administered to the subject contacts the upper third of the nasal cavity of the subject.
10 . The method of claim 1 , wherein at least 70% of the full-length IgG administered to the subject contacts the upper third of the nasal cavity of the subject.
11 . The method of claim 1 , wherein at least 50% of the full-length IgG administered to the subject contacts the olfactory epithelium of the subject.
12 . The method of claim 1 , wherein at least 60% of the full-length IgG administered to the subject contacts the olfactory epithelium of the subject.
13 . The method of claim 1 , wherein at least 70% of the full-length IgG administered to the subject contacts the olfactory epithelium of the subject.
Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 15, 2025
From: BAXALTA GMB¿; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 072035/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 15, 2025
From: BAXTER HEALTHCARE SA
To: BAXALTA GMB¿; BAXALTA INCORPORATED
Reel/Frame 072489/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 15, 2025
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 072490/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 14, 2025
From: FREY, WILLIAM H., II; HANSON, LEAH RANAE BRESIN
To: HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
Reel/Frame 072023/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 14, 2025
From: POKROPINSKI, SHARON; RAUSA, FRANCISCO M., III
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 072026/0478 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 14, 2025
From: HEALTHPARTNERS INSTITUTE FOR EDUCATION AND RESEARCH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 072026/0788 →
Continuity (7)
Provisional Application
61862814
· Aug 6, 2013
Provisional Application
61769673
· Feb 26, 2013
References Cited (71)
US 5624898A
· Frey, II
· 1997
[cited by applicant]
US 6715485B1
· Djupesland
· 2004
[cited by applicant]
US 20040101909A1
· Lemieux et al.
· 2004
[cited by applicant]
US 20070254889A1
· Jin et al.
· 2007
[cited by applicant]
US 20080305077A1
· Frey, II et al.
· 2008
[cited by applicant]
US 20110151393A1
· Frey, II et al.
· 2011
[cited by applicant]
WO WO96022802A1
· 1996
[cited by applicant]
WO WO0160420A1
· 2001
[cited by applicant]
WO WO03028668A2
· 2003
[cited by applicant]
WO WO2006091332A2
· 2006
[cited by applicant]
WO WO2007074880A1
· 2007
[cited by applicant]
WO WO2007095616A2
· 2007
[cited by applicant]
WO WO2007106617A2
· 2007
[cited by applicant]
WO WO2009058957A2
· 2009
[cited by applicant]
WO WO2009111240A1
· 2009
[cited by applicant]
WO WO2011095543A1
· 2011
[cited by applicant]
WO WO2011150284A2
· 2011
[cited by applicant]
Heilmann et al., Histochem. and Cell Biol., 113:241-245, (Year: 2000).
[cited by examiner]
Achiron, A., “Winning combination: the additive/synergistic benefits of IVIg in corticosteroid refractory optic neuritis,” European Journal of Neureology, 2008, vol. 15, p. 1145.
[cited by applicant]
Achiron, A., et al., “Immunoglobulin Treatment in Refractory Myasthenia Gravis,” Muscle & Nerve, Apr. 2000, vol. 23, pp. 551-555.
[cited by applicant]
Akassoglou, K. et al., “Oligodendrocyte Apoptosis and Primary Demyelination Induced by Local TNF/p55TNF Receptor Signaling in the Central Nervous System of Transgenic Mice,” American Journal of Pathology, Sep. 1998, vol…
[cited by applicant]
Athwal, G.S., “The Emergence of Antibody Fragments and Derivatives,” Innovations in Pharmaceutical Technology, Jul. 2009, pp. 46-48.
[cited by applicant]
Awad, A. et al., “Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles, Pathophysiology and Therapeutic Choices,” Current Neuropharmacology, 2011, vol. 9, pp. 417-428.
[cited by applicant]
Bohmwald, K. et al., “Central nervous system alterations caused by infection with the human respiratory syncytial virus,” Rev. Med. Virol., 2014, 13 pages.
[cited by applicant]
Bolli, R. et al., “L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions,” Biologicals, 2010, vol. 38, pp. 150-157.
[cited by applicant]
Cattepoel, S. et al., “Chronic Intranasal Treatment with an Anti Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease,” PLoS One, Apr. 2011, vol. 6, No. 4, pp. 1-13.
[cited by applicant]
Chauhan, N. et al., “Intranasal Passive Immunization Using WGA-Modified Oligomer Antibodies Greatly Improves Learning and Memory in Alzheimer's 5XFAD Mice,” Poster Presentation in Alzheimer's & Dementia, Jul. 14-19, 201…
[cited by applicant]
Dalakas, M.C., “Update on the Clinical Use and Mechanisms of Action of IVIG in the Treatment of Autoimmune Neurological Disorders,” Infusion Supplement, vol. 16, No. 5, Sep./Oct. 2010, pp. 1-11.
[cited by applicant]
Dodel, R. et al., “Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial,” Lancet Neurol, 2013, vol. 12, pp. 233-24…
[cited by applicant]
Dodel, R.C. et al., “Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease,” J Neurol Neurosurg Psychiatry, 2004, vol. 75, pp. 1472-1474.
[cited by applicant]
Elovaara, I. et al., “Intravenous Immunoglobulins Are a Therapeutic Option in the Treatment of Multiple Sclerosis Relapse,” Clinical Neuropharmacology, Mar./Apr. 2011, vol. 34, No. 2, pp. 84-89.
[cited by applicant]
Ertekin-Taner, N., “Genetics of Alzheimer's Disease: A Centennial Review,” Neurol Clin., Aug. 2007, vol. 25, No. 3, 43 pages.
[cited by applicant]
Fazekas, F. et al., “Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis,” Lancet, Mar. 1, 1997, vol. 349, pp. 589-593.
[cited by applicant]
Fillit, H. et al., “IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders,” Neurology, 2009, vol. 3, pp. 180-185.
[cited by applicant]
Fu, H.J. et al., “Amyloid-B Immunotherapy for Alzheimer's' Disease,” CNS Neurol Disord Drug Targets, Apr. 2010, vol. 9, No. 2, pp. 197-206.
[cited by applicant]
Haley, M. et al., “The Role for Intravenous Immunoglobulin in the Treatment of West Nile Virus Encephalitis,” Clinical Infectious Disease, Sep. 15, 2003, vol. 37, pp. e-88-90.
[cited by applicant]
Harmsen, M.M. et al., “Properties, production, and applications of camelid single-domain antibody fragments,” Appl Microbiol Biotechnol, 2007, vol. 77, pp. 13-22.
[cited by applicant]
Imbach, P. et al., “High-Dose Intravenous Gammaglobulin for Idiopathic Thrombocytopeniarpura in Childhood,” The Lancet, Jun. 6, 1981, pp. 1228-1231.
[cited by applicant]
International Search Report mailed Jun. 17, 2014, for International Patent Application No. PCT/US2014/018426, 5 pages.
[cited by applicant]
Johnson, N.J. et al., “Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures,” Mol Pharm., Jun. 7, 2010, vol. 7, No. 3, pp. 884-893.
[cited by applicant]
Kolobov, V.V. et al., “Effect of antibodies to glutamate on caspase-3 activity in brain structures of rats with experimental Alzheimer's disease,” Bull Exp Biol Med, Feb. 2013, 154(4_:425-427. Abstract, 2 pages.
[cited by applicant]
Kraus, D. et al., “Schilder's disease: Non-invasive diagnosis and successful treatment with human immunoglobulins,” Official Journal of the European Paediatric Neurology Society, 2012, vol. 16, pp. 206-207.
[cited by applicant]
Leong, H. et al., “Unlabeled Uses of Intravenous Immune Globulin,” Am J Health Syst Pharm, 2008; 65(19):1815-1824.
[cited by applicant]
Magga, J. et al., “Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease,” Journal of Neuroinflammation, 2010, vol. 7, No. 90, pp. 1-15.
[cited by applicant]
Mirra, S.S. et al., “Making the Diagnosis of Alzheimer's Disease, A Primer for Practicing Pathologists,” Diagnosing Alzheimer's Disease, Feb. 1993, vol. 117, No. 2, pp. 132-144.
[cited by applicant]
Okun, M.S., MD., et al., “Antiphospholipid-Associated Recurrent Chorea and Ballism in a Child With Cerebral Palsy,” Pediatr Neurol, 2000, vol. 23, pp. 62-63.
[cited by applicant]
Orange, J.S. et al., “Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology,” J Allergy C…
[cited by applicant]
Orbach, H. et al., “Intravenous Immunoglobulin, Adverse Effects and Safe Administration,” Clinical Reviews in Allergy and Immunology, 2005, vol. 29, pp. 173-184.
[cited by applicant]
Pardridge, W.M., “Blood-Brain Barrier Drug Targeting: The Future Development of Brain Drug Development,” Molecular Interventions, Mar. 2003, vol. 3, No. 2, pp. 90-105.
[cited by applicant]
Pardridge, W.M., “Drug and Gene Targeting to the Brain with Molecular Trojan Horses,” Nature Reviews, Feb. 2002, vol. 1, pp. 131-139.
[cited by applicant]
Patrias, L.M. et al., “Specific antibodies to soluble alpha-synuclein conformation in intravenous immunoglobulin preparations,” Clinical and Experimental Immunology, 2010, vol. 161, pp. 527-535.
[cited by applicant]
Perl, D.P., “Neuropathology of Alzheimer's Disease and Related Disorders,” Dementia, Nov. 2000, vol. 18, No. 4, pp. 847-864.
[cited by applicant]
Perlmutter, S.J. et al., “Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood,” The Lancet, Oct. 2, 1999, vol. 354, pp. 1153-1158.
[cited by applicant]
Pohl, D. et al., “Treatment of Acute Disseminated Encephalomyelitis,” Current Treatment Options in Neurology, 2012, vol. 14, pp. 264-275.
[cited by applicant]
Prasad et al. (1998) “Mechanisms of Action of Intravenous Immunoglobulin (IVIg) in Immune-Mediated Diseases,” Contemporary Immunology: Autoimmune Reactions, p. 383.
[cited by applicant]
Puli, L. et al., “Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease,” Journal of Neuroinflammation, 2012, vol. 9, No. 105, pp. 1-19.
[cited by applicant]
Relkin, N.R. et al., “18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer's disease,” Neurobiology of Aging, 2009, vol. 30, pp. 1728-1736.
[cited by applicant]
Smith, L.M. et al., “Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity,” International Immunopharmacology, 2012, vol. 14, pp. 550-557.
[cited by applicant]
Snider, L.A. et al., “Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders: Case Report and Literature Report,” Journal of Child and Adolescent Psychopharmacology, 2003, vol. 13, Suppl 1, pp. S81-S88.
[cited by applicant]
St-Amour, et al., “Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease,” J Neuroinflammation, 2012, vol. 9, p. 234.
[cited by applicant]
Stangel, M., “New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins,” Therapeutic Advances in Neurological Disorders, 2008, vol. 1, No. 2, pp. 115-124.
[cited by applicant]
Stevenson, B.R. et al., “The epithelial tight junction: Structure, function and preliminary biochemical characterization,” Molecular and Cellular Biochemistry, 1988, vol. 83, pp. 129-145.
[cited by applicant]
Stiehm, E.R., “Lessons From Kawasaki Disease: All Brands of IVIG Are Not Equal,” The Journal of Pediatrics, Jan. 2006, Editorials, pp. 6-8.
[cited by applicant]
Swedo, S.E., “Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS),” Molecular Psychiatry, 2002, vol. 7, S24-S25.
[cited by applicant]
Tselis, A. et al., “Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin,” European Journal of Neurology, 2008, vol. 15, pp. 1163-1167.
[cited by applicant]
Vo, A.A. et al., “Safety and Adverse Events Profiles of Intravenous Gammaglobulin Products Used for Immunomodulation: A Single-Center Experience,” Clin J Am Soc Nephrol, 2006, vol. 1, pp. 844-852.
[cited by applicant]
Webster, S.J. et al., “Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models,” Frontiers in Genetics, Apr. 2014, vol. 5, No. 88, p. 123.
[cited by applicant]
Weltzin, R. et al., “Intranasal Antibody Prophylaxis for Protection against Viral Disease,” Clinical Microbiology Reviews, Jul. 1999, vol. 12, No. 3, pp. 383-393.
[cited by applicant]
Wiles, C.M. et al., “Intravenous immunoglobulin in neurological disease: a specialist review,” J Neurol Neurosurg Psychiatry, 2002, vol. 72, pp. 440-448.
[cited by applicant]
Xiao, C. et al., “Brain Transit and Ameliorative Effects of Intranasally Delivered Anti-Amyloid-β Oligomer Antibody in 5XFAD Mice,” J Alzheimers Dis., 2013, vol. 35, No. 4, pp. 777-778.
[cited by applicant]
Xiao, C. et al., “Spatial acquisition learning is remarkably restored after intranasal administration of WGA-conjugated NU4 antibody in 5XFAD mice during early plaque stage,” Neuroscience, 2012, presentation abstract, P…
[cited by applicant]